Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
157P - Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: A phase IV study (ID 198)
12:30 - 13:00 | Author(s): A. Abdelaziz
The oral, irreversible ErbB family blocker, afatinib, is approved as first-line treatment for patients with EGFR mutation-positive (EGFRm+) NSCLC, demonstrating superior progression-free survival (PFS) and tolerability versus platinum-based chemotherapy. However, chemotherapy is still commonly used as first-line therapy in this patient population. In the LUX-Lung 2 study, second-line afatinib demonstrated clinical activity and an acceptable safety profile in patients with advanced NSCLC harbouring common EGFR (Del19/L858R) mutations following chemotherapy; however, the starting dose was 50 mg/day for most patients. Here, we report efficacy and safety of second-line afatinib at the approved dose of 40 mg/day in this patient population.
In this open-label, single-arm Phase IV study, tyrosine kinase inhibitor-naïve patients with EGFRm+ (Del19/L858R) NSCLC who progressed after failure of first-line chemotherapy received afatinib (starting dose 40 mg/day) until disease progression or other reasons necessitating withdrawal. The primary endpoint was investigator-assessed objective response (OR); secondary endpoints were PFS and disease control. Safety was also assessed.
The study was conducted across 24 sites in 7 countries. Sixty patients were enrolled into the study and treated with afatinib for a median duration of 11.5 months. The mean age of patients was 55.9 years; 55% were female. An OR was achieved by 50% of treated patients; median duration of response was 13.8 months. 50 patients achieved disease control; median duration was 11.9 months. 39 patients experienced an event contributing to PFS, with median PFS of 10.9 months. The most common treatment-related adverse events were diarrhoea (72%), rash/acne (58%), and paronychia (27%); no deaths were related to afatinib treatment.
At the approved starting dose of 40 mg/day, second-line afatinib demonstrated efficacy and a tolerable safety profile in patients with EGFRm+ (Del19/L858R) NSCLC. The outcomes are consistent with previous studies of afatinib. These findings support the use of second-line 40 mg/day afatinib in chemotherapy pre-treated patients.
Clinical trial identification:
Legal entity responsible for the study:
S. Geater: Honoraria from AstraZeneca and Boehringer Ingelhiem, Research funding from Samsung, AstraZeneca, Boehringer Ingelhiem and Roche. D. Jovanovic: Membership on an advisory board or board of directors: Member of local and regional (Adriatic) BI AdB. R. Gaafar: Membership of advisory board: Boehringer Ingelheim, EliLilly, Astra Zeneca, MSD, Corporate sponsored research between company and NCI, Cairo University and investigator Roche International, BI, MsD. All other authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.